Karyopharm Therapeutics (NASDAQ:KPTI) Upgraded by StockNews.com to Buy Rating

StockNews.com upgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI) from a hold rating to a buy rating in a report released on Thursday.

Other equities analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Karyopharm Therapeutics in a report on Friday, November 1st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $3.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, August 7th. Piper Sandler boosted their price target on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Finally, Robert W. Baird reduced their price objective on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $5.00.

Karyopharm Therapeutics Stock Down 3.6 %

Shares of KPTI stock traded down $0.03 during trading hours on Thursday, reaching $0.81. 832,157 shares of the company’s stock were exchanged, compared to its average volume of 1,254,215. Karyopharm Therapeutics has a fifty-two week low of $0.62 and a fifty-two week high of $1.95. The business has a fifty day moving average price of $0.82 and a 200-day moving average price of $0.90.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.01. The company had revenue of $38.78 million during the quarter, compared to the consensus estimate of $37.86 million. During the same period last year, the company earned ($0.30) earnings per share. On average, equities analysts predict that Karyopharm Therapeutics will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Karyopharm Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Ikarian Capital LLC boosted its position in Karyopharm Therapeutics by 2.3% in the first quarter. Ikarian Capital LLC now owns 409,355 shares of the company’s stock valued at $618,000 after buying an additional 9,355 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Karyopharm Therapeutics in the 2nd quarter worth approximately $167,000. Point72 DIFC Ltd bought a new stake in Karyopharm Therapeutics during the 2nd quarter worth approximately $31,000. Cubist Systematic Strategies LLC acquired a new stake in Karyopharm Therapeutics during the 2nd quarter valued at $494,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Karyopharm Therapeutics in the 2nd quarter valued at $143,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).